Mechanisms of IKK Regulation of Basal and Inflammatory Osteoclastogenesis

IKK 调节基础和炎症破骨细胞生成的机制

基本信息

  • 批准号:
    7461161
  • 负责人:
  • 金额:
    $ 33.44万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-07-07 至 2013-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The transcription factor NF-(B is essential for osteoclastogenesis and is considered a key modulator of inflammatory responses. Activation of NF-(B entails induction of a large I(B kinase (IKK) complex that comprises IKK1, IKK2, and IKK(/NEMO. IKK2 and IKK1 activate the canonical (p50/p65) and non- canonical (p52/relB) NF-(B pathways, respectively. Recent studies implicate IKK2 and IKK1 as essential for osteoclastogenesis, yet the mechanisms underling this function, remain unclear. In addition, IKK2 is considered as a key mediator of inflammatory events induced by TNF, LPS, and other pro-inflammatory agents (through the classical NF-(B pathway), whereas less is known about the role of IKK1 is such responses. In the past few years we have investigated molecular pathways regulating osteoclast activity in osteolytic responses, such as inflammatory osteolysis and arthritic bone erosion, and unveiled critical regulatory steps modulating NF-(B activation in osteoclast precursors. In this regard, we find that disruption of NF-(B activation at multiple levels attenuates osteoclastogenesis and inflammatory bone erosion. Specifically, we have shown that administration of dominant-negative forms of I(B(, that resist phosphorylation by IKK2; and most recently inhibition of IKK assembly with NEMO, using a decoy NEMO binding domain (NBD) peptide, all are successful approaches to inhibit osteoclastogenesis and bone erosion, in vitro and in vivo. Most importantly, we have preliminary evidence that, 1) failure of RANKL-induced osteoclastogenesis by IKK1-null OCPs is rescued by re-introduction of IKK1 cDNA constructs, and that 2) tissue-specific deletion of IKK2 in OCPs (using CD11b-cre) results with skeletally deformed mice. It is evident that osteoclastogenesis is impaired in the absence of IKK1 or IKK2, however, the precise mechanism(s) underlying signaling of IKKs in basal and inflammatory osteoclastogenesis remain scarce. Moreover, the relative contribution of either protein to these responses is indefinite. It is also known that IKK1 and IKK2 share considerable sequence and domain similarities, albeit they maintain distinct and non-overlapping functions. Thus, we hypothesize that IKK1 and IKK2 differentially regulate basal and inflammatory osteoclastogenesis through the alternative and classical NF-(B activation pathways. Hence, clarifying the individual roles of IKKs in osteoclastogenesis by investigating the details of their molecular signaling in osteoclasts, utilizing germ-line and specific tissue deletions of the relevant genes, will enable us to design strategies and selective inhibitors directed against IKK1 and IKK2 that may be useful for regulating osteoclastogenesis and alleviating inflammatory osteolysis in various bone resorptive disorders. Thus, we propose to investigate the following specific aims: 1) Determine the molecular role of IKK1 and IKK2 in basal and inflammatory osteoclastogenesis. 2) Determine the mechanism by which tyrosine phosphorylation regulates the fate and activity of IKK2 in the osteoclast lineage and it's impact on osteoclastogenesis. 3) Determine the role of IKK1 and IKK2 in inflammatory osteolysis, in vivo. PUBLIC HEALTH RELEVANCE: The transcription factor NF-(B is essential for osteoclastogenesis and modulates inflammatory responses. NF-(B is activated by the serine kinases, I(B kinase (IKK)-1, IKK-2, and IKK(/NEMO. Gene deletions of IKK1 or IKK2 led to defects in osteoclasts and inflammatory responses. Using IKK1 and IKK2-null mice, we propose to investigate the molecular domain contributions of IKK1 and IKK2 to osteoclastogenesis and inflammatory osteolysis, as is the case in inflammatory arthritis. Our proposal holds promise to identify novel selective anti-osteolytic therapies.
描述(由申请方提供):转录因子NF-β B是破骨细胞生成所必需的,被认为是炎症反应的关键调节剂。NF-β B的活化需要诱导大的I β B激酶(IKK)复合物,其包含IKK 1、IKK 2和IKK(/NEMO. IKK 2和IKK 1分别激活经典(p50/p65)和非经典(p52/relB)NF-(B)通路.最近的研究表明IKK 2和IKK 1对于破骨细胞生成至关重要,但该功能的机制仍不清楚。此外,IKK 2被认为是TNF、LPS和其他促炎剂(通过经典NF-(B途径)诱导的炎症事件的关键介质,而关于IKK 1在这种反应中的作用知之甚少。在过去的几年中,我们研究了在溶骨性反应中调节破骨细胞活性的分子途径,如炎性骨质溶解和关节炎性骨侵蚀,并揭示了调节破骨细胞前体中NF-β B活化的关键调节步骤。在这方面,我们发现NF-β B活化在多个水平的破坏减弱了破骨细胞生成和炎性骨侵蚀。具体地说,我们已经表明,施用抗IKK 2磷酸化的I(B)的显性阴性形式;以及最近使用诱饵NEMO结合域(NBD)肽抑制IKK与NEMO的组装,都是在体外和体内抑制破骨细胞生成和骨侵蚀的成功方法。最重要的是,我们有初步证据表明,1)IKK 1-null OCP诱导RANKL诱导破骨细胞生成的失败可通过重新引入IKK 1 cDNA构建体来挽救,2)OCP中IKK 2的组织特异性缺失(使用CD 11b-cre)导致骨骼畸形小鼠。很明显,在缺乏IKK 1或IKK 2的情况下,破骨细胞发生会受损,然而,IKK在基础和炎症性破骨细胞发生中的信号传导的精确机制仍然很少。此外,这两种蛋白质对这些反应的相对贡献是不确定的。还已知IKK 1和IKK 2具有相当大的序列和结构域相似性,尽管它们保持不同且不重叠的功能。因此,我们假设IKK 1和IKK 2通过替代的和经典的NF-β B活化途径,对基础和炎性破骨细胞的生成进行不同的调节。因此,通过研究IKK在破骨细胞中的分子信号传导细节,利用相关基因的种系和特定组织缺失,澄清IKK在破骨细胞生成中的个体作用,将使我们能够设计针对IKK 1和IKK 2的策略和选择性抑制剂,这些策略和选择性抑制剂可能有助于调节破骨细胞生成和减轻各种骨吸收疾病中的炎性骨质溶解。因此,我们建议研究以下具体目标:1)确定IKK 1和IKK 2在基础和炎性破骨细胞生成中的分子作用。2)确定酪氨酸磷酸化调节破骨细胞谱系中IKK 2的命运和活性的机制及其对破骨细胞生成的影响。3)确定IKK 1和IKK 2在体内炎性骨质溶解中的作用。公共卫生相关性:转录因子NF-β B对破骨细胞生成和调节炎症反应至关重要。NF-B由丝氨酸激酶I(B激酶(IKK)-1、IKK-2和IKK(/NEMO. IKK 1或IKK 2的基因缺失导致破骨细胞和炎症反应的缺陷。使用IKK 1和IKK 2-null小鼠,我们建议研究IKK 1和IKK 2对破骨细胞生成和炎性骨质溶解的分子结构域贡献,就像在炎性关节炎中的情况一样。我们的建议有希望确定新的选择性抗溶骨性疗法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

YOUSEF ABU-AMER其他文献

YOUSEF ABU-AMER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('YOUSEF ABU-AMER', 18)}}的其他基金

Regulation of Osteoclastogenesis and Inflammatory Osteolysis
破骨细胞生成和炎性骨质溶解的调节
  • 批准号:
    10681786
  • 财政年份:
    2023
  • 资助金额:
    $ 33.44万
  • 项目类别:
Animal Models of Joint Injury and Disease
关节损伤和疾病的动物模型
  • 批准号:
    10602567
  • 财政年份:
    2019
  • 资助金额:
    $ 33.44万
  • 项目类别:
Animal Models of Joint Injury and Disease
关节损伤和疾病的动物模型
  • 批准号:
    10388083
  • 财政年份:
    2019
  • 资助金额:
    $ 33.44万
  • 项目类别:
Mechanisms of Physiologic and Pathologic Osteoclastogenesis
破骨细胞发生的生理和病理机制
  • 批准号:
    10380048
  • 财政年份:
    2018
  • 资助金额:
    $ 33.44万
  • 项目类别:
Mechanisms of Physiologic and Pathologic Osteoclastogenesis
破骨细胞发生的生理和病理机制
  • 批准号:
    9889901
  • 财政年份:
    2018
  • 资助金额:
    $ 33.44万
  • 项目类别:
Molecular Mechanisms Underlying Tak1 Function in Osteoclasts
破骨细胞中 Tak1 功能的分子机制
  • 批准号:
    8635282
  • 财政年份:
    2008
  • 资助金额:
    $ 33.44万
  • 项目类别:
Molecular Mechanisms Underlying Tak1 Function in Osteoclasts
破骨细胞中 Tak1 功能的分子机制
  • 批准号:
    8830431
  • 财政年份:
    2008
  • 资助金额:
    $ 33.44万
  • 项目类别:
Mechanisms of IKK Regulation of Basal and Inflammatory Osteoclastogenesis
IKK 调节基础和炎症破骨细胞生成的机制
  • 批准号:
    7793408
  • 财政年份:
    2008
  • 资助金额:
    $ 33.44万
  • 项目类别:
Molecular Mechanisms Underlying Tak1 Function in Osteoclasts
破骨细胞中 Tak1 功能的分子机制
  • 批准号:
    8501884
  • 财政年份:
    2008
  • 资助金额:
    $ 33.44万
  • 项目类别:
Molecular Mechanisms Underlying Tak1 Function in Osteoclasts
破骨细胞中 Tak1 功能的分子机制
  • 批准号:
    9017945
  • 财政年份:
    2008
  • 资助金额:
    $ 33.44万
  • 项目类别:

相似海外基金

A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
  • 批准号:
    24K02286
  • 财政年份:
    2024
  • 资助金额:
    $ 33.44万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
  • 批准号:
    2420924
  • 财政年份:
    2024
  • 资助金额:
    $ 33.44万
  • 项目类别:
    Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
  • 批准号:
    10596047
  • 财政年份:
    2023
  • 资助金额:
    $ 33.44万
  • 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
  • 批准号:
    10742028
  • 财政年份:
    2023
  • 资助金额:
    $ 33.44万
  • 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
  • 批准号:
    BB/X017540/1
  • 财政年份:
    2023
  • 资助金额:
    $ 33.44万
  • 项目类别:
    Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
  • 批准号:
    LP210301365
  • 财政年份:
    2023
  • 资助金额:
    $ 33.44万
  • 项目类别:
    Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
  • 批准号:
    10730832
  • 财政年份:
    2023
  • 资助金额:
    $ 33.44万
  • 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
  • 批准号:
    10659841
  • 财政年份:
    2023
  • 资助金额:
    $ 33.44万
  • 项目类别:
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
  • 批准号:
    BB/V016067/1
  • 财政年份:
    2022
  • 资助金额:
    $ 33.44万
  • 项目类别:
    Research Grant
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
  • 批准号:
    576545-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 33.44万
  • 项目类别:
    Idea to Innovation
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了